

IN THE CLAIMS:

Please amend claims 23, 63 and 81.

This listing of claims will replace all prior versions, and listings of the claims in the application.

Listing of the claims

1-22. **(Canceled)**

23. **(Currently Amended)** A method of treating an individual suspected of suffering from metastatic colorectal cancer comprising the step of administering to said individual a ~~therapeutically effective amount of a~~ pharmaceutical composition that comprises:

- a) ~~an ST~~ a heat stable enterotoxin (ST) receptor ligand in an amount effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual;
 - b) an active agent in an amount effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual, wherein the active agent causes cell death, inhibits cell division or induces differentiation; and
 - c) a pharmaceutically acceptable carrier or diluent
- wherein said ST receptor ligand is an antibody, Fab or F(AB)₂.

Claims 24-27. **(Canceled)**

28. **(Previously Presented)** The method of claim 23 wherein said ST receptor ligand is an antibody.

29. **(Previously Presented)** The method of claim 23 wherein said active agent causes cell death.

30. **(Previously Presented)** The method of claim 23 wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, *cis*-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.

31-35. **(Canceled)**

36. **(Previously Presented)** The method of claim 23 wherein said pharmaceutical composition is administered intravenously.

37-49. **(Canceled)**

50. **(Previously Presented)** The method of claim 30 wherein said ST receptor ligand is an antibody.

51. **(Previously Presented)** The method of claim 36 wherein said ST receptor ligand is an antibody.

52. **(Previously Presented)** The method of claim 23 wherein said ST receptor ligand is a Fab.

53. **(Previously Presented)** The method of claim 30 wherein said ST receptor ligand is a Fab.

- | | |
|--|---|
| 54. (Previously Presented)
ligand is a Fab. | The method of claim 36 wherein said ST receptor |
| 55. (Previously Presented)
ligand is a F(ab) ₂ . | The method of claim 23 wherein said ST receptor |
| 56. (Previously Presented)
ligand is a F(ab) ₂ . | The method of claim 30 wherein said ST receptor |
| 57. (Previously Presented)
ligand is a F(ab) ₂ . | The method of claim 36 wherein said ST receptor |
| 58. (Previously Presented)
ligand is an antibody. | The method of claim 29 wherein said ST receptor |
| 59. (Previously Presented)
ligand is a F(ab). | The method of claim 29 wherein said ST receptor |
| 60. (Previously Presented)
ligand is a F(ab) ₂ . | The method of claim 29 wherein said ST receptor |
| 61. (Previously Presented)
a chemotherapeutic agent. | The method of claim 23 wherein said active agent is |
| 62. (Previously Presented)
a cytotoxic chemotherapeutic agent. | The method of claim 23 wherein said active agent is |

63. **(Currently Amended)** A method of treating an individual suffering from metastatic colorectal cancer comprising the step of administering to said individual ~~a therapeutically effective~~ an amount of a pharmaceutical composition that effective to therapeutically eliminate metastasized colorectal cancer cells, wherein said pharmaceutical compositions comprises:

- a) ~~an ST~~ a heat stable enterotoxin (ST) receptor ligand;
 - b) an active agent, wherein the active agent causes cell death, inhibits cell division or induces differentiation: and
 - c) a pharmaceutically acceptable carrier or diluent,
- wherein said ST receptor ligand is an antibody, Fab or F(AB)₂.

64. **(Previously Presented)** The method of claim 63 wherein said ST receptor ligand is an antibody.

65. **(Previously Presented)** The method of claim 63 wherein said active agent causes cell death.

66. **(Previously Presented)** The method of claim 63 wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, *cis*-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.

67. **(Previously Presented)** The method of claim 63 wherein said pharmaceutical composition is administered intravenously.

68. **(Previously Presented)** The method of claim 66 wherein said ST receptor ligand is an antibody.
69. **(Previously Presented)** The method of claim 67 wherein said ST receptor ligand is an antibody.
70. **(Previously Presented)** The method of claim 63 wherein said ST receptor ligand is a Fab.
71. **(Previously Presented)** The method of claim 66 wherein said ST receptor ligand is a Fab.
72. **(Previously Presented)** The method of claim 67 wherein said ST receptor ligand is a Fab.
73. **(Previously Presented)** The method of claim 63 wherein said ST receptor ligand is a F(ab)₂.
74. **(Previously Presented)** The method of claim 67 wherein said ST receptor ligand is a F(ab)₂.
75. **(Previously Presented)** The method of claim 67 wherein said ST receptor ligand is a F(ab)₂.
76. **(Previously Presented)** The method of claim 65 wherein said ST receptor ligand is an antibody.

77. **(Previously Presented)** The method of claim 65 wherein said ST receptor ligand is a Fab.
78. **(Previously Presented)** The method of claim 65 wherein said ST receptor ligand is a F(ab)₂.
79. **(Previously Presented)** The method of claim 63 wherein said active agent is a chemotherapeutic agent.
80. **(Previously Presented)** The method of claim 63 wherein said active agent is a cytotoxic chemotherapeutic agent.
81. **(Currently Amended)** A method of treating an individual suffering from metastatic colorectal cancer comprising the step of administering to said individual a ~~therapeutically effective amount of a~~ conjugated compound in an amount effective to cause a cytotoxic or cytostatic effect on metastasized colorectal cancer cells without causing lethal side effects on the individual, wherein said conjugated compound ~~that~~ comprises
- a) ~~an ST~~ a heat stable enterotoxin (ST) receptor binding moiety which is an antibody or a fragment thereof;
 - b) an active moiety which is an active agent that causes cell death, inhibits cell division or induces differentiation.
82. **(Previously Presented)** The method of claim 81 wherein said ST receptor binding moiety is an antibody.
83. **(Previously Presented)** The method of claim 81 wherein said ST receptor binding moiety is a FAb.

84. **(Previously Presented)** The method of claim 81 wherein said ST receptor binding moiety is an F(Ab)₂.
85. **(Previously Presented)** The method of claim 81 wherein said active moiety is an active agent that causes cell death.
86. **(Previously Presented)** The method of claim 81 wherein said active moiety is a chemotherapeutic agent.
87. **(Previously Presented)** The method of claim 81 wherein said active moiety is a cytotoxic chemotherapeutic agent.
88. **(Previously Presented)** The method of claim 81 wherein said active moiety is selected from the group consisting of methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, *cis*-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.
89. **(Previously Presented)** The method of claim 81 wherein said conjugated compound is administered intravenously.